Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
OTLK
$0.59
+3.13%
OTLK
· Outlook Therapeutics, Inc.
$0.59
+0.02 (+3.13%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 18, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Because our cash and cash equivalents, together with $51.1 million of net proceeds from our August 2026 Offering, will not be adequate to fund our currently planned operations through at least the 12 months from the date of this Quarterly Report, there is substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 18, 2026
Market Cap
$155.68M
Shares
243.45M
Volume · Oct 2
5.62M
Avg daily vol (3M)
13.63M
All webcasts
Earnings call · FY2022 Q2
Outlook Therapeutics, Inc. (OTLK) Q2 2022 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Diluted EPS
-$1.80
Net income
-$19.70M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed May 13, 2022 · complete as-filed document
SEC periodic report
10-Q report
Filed May 13, 2022 · complete as-filed document